PHARMACOECONOMIC ASSESSMENT OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN IMMUNIZATION OF CHILDREN IN RUSSIAN FEDERATION
Aim: cost-effectiveness assessment and budget impact analysis for 13-valent pneumococcal conjugate vaccine (PCV13) in infant immunization program in Russian Federation. Materials and methods: 10 year modeling with social perspective (direct medical and indirect costs and life expectancy with discoun...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
"Paediatrician" Publishers LLC
2014-01-01
|
| Series: | Вопросы современной педиатрии |
| Subjects: | |
| Online Access: | https://vsp.spr-journal.ru/jour/article/view/226 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850024335453978624 |
|---|---|
| author | A. V. Rudakova A. A. Baranov Yu. V. Lobzin N. I. Briko L. S. Namazova-Baranova V. K. Tatochenko S. M. Kharit S. V. Sidorenko I. S. Koroleva R. S. Kozlov N. A. Mayanskii M. P. Kostinov N. F. Snegova |
| author_facet | A. V. Rudakova A. A. Baranov Yu. V. Lobzin N. I. Briko L. S. Namazova-Baranova V. K. Tatochenko S. M. Kharit S. V. Sidorenko I. S. Koroleva R. S. Kozlov N. A. Mayanskii M. P. Kostinov N. F. Snegova |
| author_sort | A. V. Rudakova |
| collection | DOAJ |
| description | Aim: cost-effectiveness assessment and budget impact analysis for 13-valent pneumococcal conjugate vaccine (PCV13) in infant immunization program in Russian Federation. Materials and methods: 10 year modeling with social perspective (direct medical and indirect costs and life expectancy with discounting by 3,5% per year) and population effect based on results of clinical studies, global PCV13 use and Russian epidemiological data has been established. Budget impact has been analyzed without discounting. Direct effect was assessed by influence on pneumococcal meningitis, bacteremia, pneumonia and acute otitis media (AOM) incidence, population effect — by pneumococcal meningitis and hospitalized all-cause pneumonia incidence. Results: Possible PCV13 effectiveness was estimated as 76,6% for invasive pneumococcal diseases (IPD) and 23,7% for hospitalized cases of AOM. Vaccination (per 100 000 vaccinated infants) can prevent 13,8 lethal cases in vaccinated population and 171,1 — in unvaccinated population. Cost-effectiveness ratio for PCV13 is estimated as 32,400 rubles / LYG and 32,400 rubles / QALY. Cost of 1 lethal case prevention is 140 100 rubles, additional cost for 10 years is 111,5 rubles per child. Conclusions: PCV13 mass vaccination of infants in Russian Federation is highly cost-effective and will significantly cut expenses due to pneumococcal diseases treatment. |
| format | Article |
| id | doaj-art-44fcc2b1b13c45e5a8288c93589501f0 |
| institution | DOAJ |
| issn | 1682-5527 1682-5535 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | "Paediatrician" Publishers LLC |
| record_format | Article |
| series | Вопросы современной педиатрии |
| spelling | doaj-art-44fcc2b1b13c45e5a8288c93589501f02025-08-20T03:01:07Zeng"Paediatrician" Publishers LLCВопросы современной педиатрии1682-55271682-55352014-01-01131515910.15690/vsp.v13i1.911226PHARMACOECONOMIC ASSESSMENT OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN IMMUNIZATION OF CHILDREN IN RUSSIAN FEDERATIONA. V. Rudakova0A. A. Baranov1Yu. V. Lobzin2N. I. Briko3L. S. Namazova-Baranova4V. K. Tatochenko5S. M. Kharit6S. V. Sidorenko7I. S. Koroleva8R. S. Kozlov9N. A. Mayanskii10M. P. Kostinov11N. F. Snegova12Scientific Research Institute of Children Infections, St. PetersburgScientific Centre of Children Health of RAMS, Moscow I.M. Sechenov First Moscow State Medical UniversityScientific Research Institute of Children Infections, St. PetersburgI.M. Sechenov First Moscow State Medical UniversityScientific Centre of Children Health of RAMS, Moscow I.M. Sechenov First Moscow State Medical University N.I. Pirogov Russian National Research Medical University, MoscowScientific Centre of Children Health of RAMS, MoscowScientific Research Institute of Children Infections, St. PetersburgScientific Research Institute of Children Infections, St. PetersburgCentral Scientific Research Institute of Epidemiology, MoscowScientific Research Institute of Antimicrobial Chemotherapy, SmolenskScientific Centre of Children Health of RAMS, Moscow I.M. Sechenov First Moscow State Medical UniversityI.I. Mechnikov Scientific Research Institute of Vaccines and Serums of RAMS, MoscowInstitute of Immunology, MoscowAim: cost-effectiveness assessment and budget impact analysis for 13-valent pneumococcal conjugate vaccine (PCV13) in infant immunization program in Russian Federation. Materials and methods: 10 year modeling with social perspective (direct medical and indirect costs and life expectancy with discounting by 3,5% per year) and population effect based on results of clinical studies, global PCV13 use and Russian epidemiological data has been established. Budget impact has been analyzed without discounting. Direct effect was assessed by influence on pneumococcal meningitis, bacteremia, pneumonia and acute otitis media (AOM) incidence, population effect — by pneumococcal meningitis and hospitalized all-cause pneumonia incidence. Results: Possible PCV13 effectiveness was estimated as 76,6% for invasive pneumococcal diseases (IPD) and 23,7% for hospitalized cases of AOM. Vaccination (per 100 000 vaccinated infants) can prevent 13,8 lethal cases in vaccinated population and 171,1 — in unvaccinated population. Cost-effectiveness ratio for PCV13 is estimated as 32,400 rubles / LYG and 32,400 rubles / QALY. Cost of 1 lethal case prevention is 140 100 rubles, additional cost for 10 years is 111,5 rubles per child. Conclusions: PCV13 mass vaccination of infants in Russian Federation is highly cost-effective and will significantly cut expenses due to pneumococcal diseases treatment.https://vsp.spr-journal.ru/jour/article/view/226pneumococcal diseases13-valent pneumococcal conjugate vaccinecost-effectivenessbudget impact analysis |
| spellingShingle | A. V. Rudakova A. A. Baranov Yu. V. Lobzin N. I. Briko L. S. Namazova-Baranova V. K. Tatochenko S. M. Kharit S. V. Sidorenko I. S. Koroleva R. S. Kozlov N. A. Mayanskii M. P. Kostinov N. F. Snegova PHARMACOECONOMIC ASSESSMENT OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN IMMUNIZATION OF CHILDREN IN RUSSIAN FEDERATION Вопросы современной педиатрии pneumococcal diseases 13-valent pneumococcal conjugate vaccine cost-effectiveness budget impact analysis |
| title | PHARMACOECONOMIC ASSESSMENT OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN IMMUNIZATION OF CHILDREN IN RUSSIAN FEDERATION |
| title_full | PHARMACOECONOMIC ASSESSMENT OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN IMMUNIZATION OF CHILDREN IN RUSSIAN FEDERATION |
| title_fullStr | PHARMACOECONOMIC ASSESSMENT OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN IMMUNIZATION OF CHILDREN IN RUSSIAN FEDERATION |
| title_full_unstemmed | PHARMACOECONOMIC ASSESSMENT OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN IMMUNIZATION OF CHILDREN IN RUSSIAN FEDERATION |
| title_short | PHARMACOECONOMIC ASSESSMENT OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN IMMUNIZATION OF CHILDREN IN RUSSIAN FEDERATION |
| title_sort | pharmacoeconomic assessment of 13 valent pneumococcal conjugate vaccine in immunization of children in russian federation |
| topic | pneumococcal diseases 13-valent pneumococcal conjugate vaccine cost-effectiveness budget impact analysis |
| url | https://vsp.spr-journal.ru/jour/article/view/226 |
| work_keys_str_mv | AT avrudakova pharmacoeconomicassessmentof13valentpneumococcalconjugatevaccineinimmunizationofchildreninrussianfederation AT aabaranov pharmacoeconomicassessmentof13valentpneumococcalconjugatevaccineinimmunizationofchildreninrussianfederation AT yuvlobzin pharmacoeconomicassessmentof13valentpneumococcalconjugatevaccineinimmunizationofchildreninrussianfederation AT nibriko pharmacoeconomicassessmentof13valentpneumococcalconjugatevaccineinimmunizationofchildreninrussianfederation AT lsnamazovabaranova pharmacoeconomicassessmentof13valentpneumococcalconjugatevaccineinimmunizationofchildreninrussianfederation AT vktatochenko pharmacoeconomicassessmentof13valentpneumococcalconjugatevaccineinimmunizationofchildreninrussianfederation AT smkharit pharmacoeconomicassessmentof13valentpneumococcalconjugatevaccineinimmunizationofchildreninrussianfederation AT svsidorenko pharmacoeconomicassessmentof13valentpneumococcalconjugatevaccineinimmunizationofchildreninrussianfederation AT iskoroleva pharmacoeconomicassessmentof13valentpneumococcalconjugatevaccineinimmunizationofchildreninrussianfederation AT rskozlov pharmacoeconomicassessmentof13valentpneumococcalconjugatevaccineinimmunizationofchildreninrussianfederation AT namayanskii pharmacoeconomicassessmentof13valentpneumococcalconjugatevaccineinimmunizationofchildreninrussianfederation AT mpkostinov pharmacoeconomicassessmentof13valentpneumococcalconjugatevaccineinimmunizationofchildreninrussianfederation AT nfsnegova pharmacoeconomicassessmentof13valentpneumococcalconjugatevaccineinimmunizationofchildreninrussianfederation |